A Phase 1, Open-label, Single-dose Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Volunteers
Latest Information Update: 08 Nov 2024
At a glance
- Drugs Teprotumumab (Primary)
- Indications Graves ophthalmopathy
- Focus Pharmacokinetics
- Sponsors Amgen
Most Recent Events
- 08 Nov 2024 New trial record